Collagen Crosslinks, any Method

Collagen crosslink testing is covered principally to identify elevated bone resorption and to monitor or predict response to FDA‑approved antiresorptive and related therapies, especially in younger beneficiaries and patients at risk for rapid bone loss (e.g., glucocorticoid use). Testing requires one or two baseline urine assays collected on separate days and structured follow‑up (≈3 months after therapy start, 12 months after the 3‑month test, then annually), is generally not useful for most beneficiaries aged ≥65, and must respect FDA labeling restrictions for specific assays.

"Collagen crosslink testing is covered to identify individuals with elevated bone resorption who have osteoporosis and are being monitored for response to therapy."

Sign up to see full coverage criteria, indications, and limitations.